| Nasolacrimal Duct Obstruction Treatments | Lifetime | 1 | AU 1 | 99.52 |
| Cancer and Skin Lesions | Lifetime | 67 | AU 4 | 99.14 |
| Head and Neck Surgical Oncology | Lifetime | 128 | AU 5 | 99.18 |
| Ophthalmology and Eye Disorders | Lifetime | 72 | AU 3 | 98.93 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 70 | AU 7 | 98.96 |
| Oral and Maxillofacial Pathology | Lifetime | 176 | AU 4 | 98.86 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 31 | AU 1 | 98.29 |
| Salivary Gland Tumors Diagnosis and Treatment | Lifetime | 145 | AU 2 | 98.90 |
| Facial Rejuvenation and Surgery Techniques | Lifetime | 49 | AU 2 | 98.66 |
| Ocular Disorders and Treatments | Lifetime | 29 | AU 1 | 97.99 |
| Sinusitis and nasal conditions | Lifetime | 129 | AU 7 | 98.40 |
| Facial Trauma and Fracture Management | Lifetime | 115 | AU 3 | 98.06 |
| Cerebral Venous Sinus Thrombosis | Lifetime | 163 | AU 4 | 97.70 |
| Ear and Head Tumors | Lifetime | 162 | AU 6 | 98.12 |
| Vascular Malformations and Hemangiomas | Lifetime | 148 | AU 2 | 96.92 |
| Ocular Oncology and Treatments | Lifetime | 162 | AU 2 | 96.96 |
| Reconstructive Facial Surgery Techniques | Lifetime | 192 | AU 3 | 97.60 |
| Ocular Surface and Contact Lens | Lifetime | 361 | AU 20 | 97.76 |
| Meningioma and schwannoma management | Lifetime | 533 | AU 5 | 97.26 |
| Traumatic Ocular and Foreign Body Injuries | Lifetime | 227 | AU 9 | 95.84 |
| Infectious Diseases and Mycology | Lifetime | 318 | AU 11 | 95.93 |
| Soft tissue tumor case studies | Lifetime | 282 | AU 3 | 96.16 |
| Autoimmune and Inflammatory Disorders | Lifetime | 302 | AU 8 | 95.78 |
| Pituitary Gland Disorders and Treatments | Lifetime | 955 | AU 22 | 95.84 |
| Bone Tumor Diagnosis and Treatments | Lifetime | 880 | AU 10 | 95.11 |
| Facial Nerve Paralysis Treatment and Research | Lifetime | 431 | AU 6 | 94.34 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 214 | AU 5 | 93.99 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 946 | AU 14 | 93.92 |
| Histiocytic Disorders and Treatments | Lifetime | 853 | AU 11 | 83.65 |
| Drug-Induced Ocular Toxicity | Lifetime | 976 | AU 25 | 63.78 |
| Nasolacrimal Duct Obstruction Treatments | 2021-2025 | 3 | AU 1 | 97.77 |
| Salivary Gland Tumors Diagnosis and Treatment | 2021-2025 | 68 | AU 2 | 96.11 |
| Ophthalmology and Eye Disorders | 2021-2025 | 48 | AU 1 | 95.63 |
| IgG4-Related and Inflammatory Diseases | 2021-2025 | 24 | AU 1 | 94.78 |
| Head and Neck Surgical Oncology | 2021-2025 | 295 | AU 5 | 91.85 |
| Sinusitis and nasal conditions | 2021-2025 | 157 | AU 7 | 93.74 |
| Cerebral Venous Sinus Thrombosis | 2021-2025 | 185 | AU 4 | 88.90 |
| Cancer and Skin Lesions | 2021-2025 | 196 | AU 3 | 85.57 |
| Otitis Media and Relapsing Polychondritis | 2021-2025 | 128 | AU 1 | 87.19 |
| Ear and Head Tumors | 2021-2025 | 259 | AU 8 | 83.38 |
| Ocular Surface and Contact Lens | 2021-2025 | 885 | AU 34 | 82.94 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 320 | AU 12 | 78.53 |
| Soft tissue tumor case studies | 2021-2025 | 211 | AU 3 | 76.80 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 678 | AU 47 | 78.68 |
| Facial Trauma and Fracture Management | 2021-2025 | 600 | AU 17 | 70.02 |
| Ocular Oncology and Treatments | 2021-2025 | 759 | AU 16 | 67.65 |
| Facial Nerve Paralysis Treatment and Research | 2021-2025 | 756 | AU 20 | 64.65 |
| Facial Rejuvenation and Surgery Techniques | 2021-2025 | 948 | AU 15 | 62.21 |
| Ocular Disorders and Treatments | 2021-2025 | 251 | AU 5 | 58.95 |
| Vascular Malformations and Hemangiomas | 2021-2025 | 823 | AU 6 | 57.47 |
| Traumatic Ocular and Foreign Body Injuries | 2021-2025 | 802 | AU 16 | 55.50 |
| Sympathectomy and Hyperhidrosis Treatments | 2021-2025 | 647 | AU 8 | 40.56 |
